Vertex Pharmaceuticals Incorporated
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vertex Pharmaceuticals Incorporated
With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.
The US biotech has nabbed a deal with Regeneron to develop bispecific cancer therapies by combining their respective technology platforms, getting $30m upfront in a positive twist of fate following a recent clinical trial challenge.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
- Other Names / Subsidiaries
- ViroChem Pharma Inc., Exonics Therapeutics, Inc., Semma Therapeutics